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Advances in Stroke 2008
Advances in Emerging Therapies
Peter Higgins, MBChB, MRCP; Kennedy R. Lees, MD, FRCP
Historically, stroke has proven to be a condition poorlyamenable to treatment, and the last year delivered its
share of neutral results in this regard. However, other studies
suggested promising areas for pursuit while a couple grabbed
the headlines and will modify clinical practice.
Thrombolysis
We can justifiably emphasize the findings of the third
European Cooperative Acute Stroke Study (ECASS-3),
which has recently confirmed the use of thrombolytic therapy
up to 4.5 hours after onset of ischemic stroke.1 The reality is
that alteplase was already a safe and highly effective treat-
ment before the results of ECASS-3 became known. How-
ever, a minority allowed their uncertainty over safety and
doubts raised by individually neutral trials to restrict imple-
mentation of this potent therapy. The latest result broadens
the range of patients who may benefit but it has implications
beyond these narrow confines. Even after accounting for the
expected low rate of symptomatic bleeding—just 2% excess
over placebo—alteplase treatment delivered a 10% absolute
increase in proportion of patients attaining excellent outcome,
indicating 3 valuable lessons. First, any residual doubts over
the safety or efficacy of intravenous alteplase early after
stroke have been annulled. Second, the challenging time
window for treatment can be relaxed, provided this is not at
the expense of slower reaction by services. Third, there is
evidently scope for further extension of treatment and en-
hancement of alteplase’s action that begs continued research.
We need to test extended patient selection, perhaps via
imaging strategies. We must also assess whether we can
enhance the extent and rapidity of reperfusion. This may
involve incoorporating ancillary measures such as antithrom-
botic therapy and blood pressure manipulation.
One of our challenges is to divorce enhancement of
reperfusion from exacerbation of serious bleeding risk. Both
better patient selection and careful pharmacological profiling
are required. By harnessing our very active clinical services
to contribute actively to research, we could make rapid
strides. The SITS register’s examination of treatment 3 to 4.5
hours after stroke onset illustrates that over 12 000 patients
were treated ‘within label’ in participating centers while
ECASS-III was enrolling.2
The EPITHET study3 used perfusion neuroimaging to
identify patients expected to benefit from thrombolytic treat-
ment beyond standard treatment windows. In patients with
perfusion-/diffusion-weighted imaging mismatch, alteplase
increased reperfusion and was associated with enhanced
functional outcome. Unfortunately, EPITHET lacked power
to confirm whether selection by imaging beyond the licensed
time window is ready to be introduced. The ECASS-3 result
and EPITHET together should convince us to redouble our
efforts to test delayed thrombolysis in carefully selected
patients who present too late for standard care.
We know that alteplase achieves reperfusion neither im-
mediately nor universally. While the evidence base for
alteplase expands, encouraging data for another thrombolytic,
tenectaplase, was presented at the International Stroke Con-
ference (ISC). In their pilot study, Molina et al4 demonstrated
better rates of recanalization and functional outcome at 3
months, against a trend toward increased hemorrhage.
Ultrasound-assisted thrombolysis may improve recanaliza-
tion rates, though increased bleeding has also been observed.
Eggers et al,5 using a transcranial ultrasound delivery device,
confirmed increased recanalization at the expense of a trend
to increased hemorrhage, leading to premature discontinua-
tion of their study. Ultrasound-assisted lysis merits more
robust safety evaluation, in which dose and delivery modality
are thoroughly evaluated. We must not let regulatory laxity
over evaluation of devices diminish our rigorous appraisal of
their potential. We await with interest the results of studies
such as TRUST, evaluating the safety and efficacy of 60
minutes’ continuous insonation of the occluded middle cere-
bral artery in patients with ischemic stroke given intravenous
alteplase.
We can refer to extensive observational data implying
efficacy of intra-arterial thrombolysis, but we lack com-
parative studies against intravenous (IV) administration.
SYNTHESIS EXP is a phase III study being designed to
assess whether local intra-arterial tissue plasminogen ac-
tivator (tPA), as compared to IV tPA, can increase survival
free from disability.
Recovery after thrombolysis requires successful restoration
and maintenance of blood flow. Intuitively, antiplatelet ther-
apy should help prevent reocclusion. Current stroke guide-
lines reflect concern that the risk of symptomatic bleeding
may be unacceptable if antithrombotic therapy is given
alongside alteplase. Such caution may be misplaced. Uytten-
boogart et al6 have published prospective observational data
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assessing the impact of antiplatelet therapy in patients under-
going thrombolysis. They confirmed an increased risk of
symptomatic intracranial hemorrhage among patients already
established on antiplatelet therapy, but report that the net
effect on functional outcome remains favorable. Such studies
reinforce the importance of measuring robust outcomes in
acute stroke, using tools that combine risk and benefit in a
unified measure, such as the modified Rankin Scale. ARTIS,
a phase III trial to confirm whether the addition of aspirin to
standard rt-PA thrombolysis offers additional benefit, is
ongoing.
Alternative antiplatelet agents suffered a setback. The
discontinuation of the AbESTT-II study due to excess bleed-
ing has raised concern about glycoprotein IIb/IIIa inhibitors
in acute stroke.7 Perhaps coronary doses do not translate to
the brain: there is no such thing as a safe drug, only one used
at the optimum dose. Other agents in this class continue to be
evaluated. Encouraging safety results were observed in the
CLEAR study for eptifibatide, used in combination with
alteplase in the acute setting.8
Old trials based on a different standard of care can unduly
impede progress. We know little about heparin use in modern
circumstances. Perhaps it is time to revisit the role of
antithrombotics in acute stroke, at least post-thrombolysis.
Antiplatelets
Results of the largest study last year, PROFESS,9 had been
eagerly anticipated to show the extent of advantage conferred
by the combination of aspirin with dipyridamole over clopi-
dogrel monotherapy. To the surprise of many, PROFESS
demonstrated that the 2 strategies are equal. Far from repre-
senting a “negative” study, this is important information that
will impact on our practice, because dipyridamole is not
universally tolerated. The interpretation has been debated
widely, but perhaps the crucial message is that although a
simple aspirin remains cheap and universally available, it is
not a panacea.
Antithrombotics
In prevention, the search for alternatives to warfarin contin-
ues because of its inherent bleeding risk and monitoring
requirements.
Full results of the Amadeus10 study were published this
year. Idraparinux was associated with significantly greater
bleeding complications than warfarin. Its safety profile does
not presently commend it as a viable alternative to warfarin.
Direct thrombin inhibitors (DTI) have also been compro-
mised by safety concerns. Further analysis of the SPORTIF
III and V trials11 among elderly patients with atrial fibrillation
demonstrated similar efficacy in stroke reduction by the DTI
ximelagatran as with warfarin. Bleeding complications were
fewer in the DTI group despite more intensive international
normalized ratio monitoring for the warfarin group than we
often see in clinical practice. However, an excess of liver
function derangement was again observed with ximelagatran.
Though ximelagatran itself seems doomed, this analysis lends
cautious optimism for DTIs as a general alternative in
patients requiring anticoagulation but in whom warfarin is
deemed inappropriate. We await results of the RE-LY study,
which evaluated dabigatran in a similar setting. We also look
forward to the Argatroban TPA Stroke Study, which is
evaluating the role of a DTI in the hyperacute setting to
augment thrombolytic therapy.
Other Avenues
Hyperglycemia is associated with adverse outcome and so
induction of normoglycemia as part of acute management
carries face validity. The disappointing results of intervention
for mildly elevated sugars in GIST-UK may relate to the
choice of glucose-potassium-insulin infusion as the means of
lowering blood sugar and/or to statistical underpowering.
Bruno et al12 instead used a continuous intravenous insulin
infusion according to sliding scale as a means for correcting
hyperglycemia in the THIS study. Greater reductions in
glucose were observed using this approach with no apparent
excess in adverse events. Their study was not powered to look
at overall outcome but demonstrated nonsignificant improve-
ments in functional outcome in the more aggressively treated
group.
A pilot study of granulocyte-colony stimulating factor (the
AXIS study13) was presented at the ISC. Based on promising
results in animal models this study sought primarily to
evaluate the safety of granulocyte-colony stimulating factor
in humans. Apparent demonstration of safety in the small
study population was supplemented with a trend toward
improvement in functional outcome in the treatment group.
This intriguing finding merits further evaluation.
Yusuyaki presented case-controlled data at the ISC sug-
gesting modest improvements in clinical outcomes with the
free radical scavenger edaravone,14 a drug with some parallels
to NXY-059 used in the SAINT program but licensed in
Japan. The ECCT-HIS study will prospectively evaluate
edaravone along with citicoline, a second potential neuropro-
tectant agent which is also under investigation in the ICTUS
trial.
A study with erythropoietin (EPO) as neuroprotectant
recently announced a negative result, possibly due to in-
creased risk of mortality in a subgroup. Whether the drug is
salvageable has yet to be determined. The REGENESIS
study, evaluating EPO and hCG in combination may provide
further answers, if an FDA hold on recruitment pending
details of the EPO study is lifted. Clinical work with a
carbamylated derivative of erythropoietin, CEPO, which is
apparently devoid of hematologic effects, was announced at
the 2008 Thrombolysis and Acute Stroke Therapy conference
in Budapest.
Finally, we must not forget that devices to assist cooling
remain under development, and that hypothermia is a poten-
tially potent natural neuroprotectant.
Summary
At least 2 large clinical trials published over the last 12
months will modify practice, in acute treatment and second-
ary prevention respectively. We have exciting support for
thrombolysis and a stimulus to expand our efforts to restore
perfusion in a wider range of patients. Elsewhere we see
encouragement that improvements in therapy are emerging,
and hope to see these flourish over the coming year.
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